Table 1.
Baseline characteristics.
| All patients (n = 7) | |
|---|---|
| Gender (n, %) | |
| Female | 2 (29) |
| Male | 5 (71) |
| Age (year; median, range) | 53 (44–74) |
| Time from diagnosis (year; median, range) | 4.3 (1.6–25.6) |
| Initial TNM stage (n, %) | |
| IB (T2 N0 M0) | 0 |
| IIB (T2-3 N0-1 M0) | 2 (29) |
| IIIA (T1-3 N1-2 M0) | 3 (43) |
| IV (any T any N M1) | 2 (29) |
| Unknown | 0 |
| Tumor extent at study entry (n, %) | |
| Locally advanced | 1 (14) |
| Metastatic | 6 (86) |
| Number of disease sites (n, %) | |
| 1 | 1 (14) |
| 2 | 2 (29) |
| ≥3 | 4 (57) |
| Mutational status (n, %) | |
| RET M918T | 4 (57) |
| MEN-IIA | 1 (14) |
| EGFR P848L | 1 (14) |
| Unknown | 1 (14) |
| Prior treatment (n, %) | |
| Surgery | 6 (86) |
| Radiation therapy | 2 (29) |
| Tyrosine kinase inhibitorx˚ | 4 (57) |
x3 patients received XL184; 1 patient showed an ongoing PR for 14 months before he became progressive; 2 had PD as best result after 12 and 24 weeks. °1 patient had vandetanib for 8 months, followed by 3 months of sunitinib, which was stopped due to side effects.